Chandra Bhagat Pharma Ltd
Incorporated in 2003, Chandra Bhagat Pharma Ltd manufactures and trades Pharmaceutical Formulations and API Products[1]
- Market Cap ₹ 43.8 Cr.
- Current Price ₹ 58.0
- High / Low ₹ 111 / 46.2
- Stock P/E 50.9
- Book Value ₹ 39.7
- Dividend Yield 0.00 %
- ROCE 6.48 %
- ROE 2.92 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 1.91% over last quarter.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.59% over past five years.
- Company has a low return on equity of 3.89% over last 3 years.
- Earnings include an other income of Rs.5.52 Cr.
- Company has high debtors of 151 days.
- Working capital days have increased from 125 days to 194 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
48.01 | 61.13 | 79.84 | 89.79 | 97.06 | 106.28 | 93.97 | 70.70 | 94.04 | 119.67 | 221.37 | 86.72 | |
46.18 | 58.13 | 76.42 | 85.41 | 92.47 | 101.69 | 90.85 | 67.02 | 91.20 | 116.33 | 228.41 | 88.17 | |
Operating Profit | 1.83 | 3.00 | 3.42 | 4.38 | 4.59 | 4.59 | 3.12 | 3.68 | 2.84 | 3.34 | -7.04 | -1.45 |
OPM % | 3.81% | 4.91% | 4.28% | 4.88% | 4.73% | 4.32% | 3.32% | 5.21% | 3.02% | 2.79% | -3.18% | -1.67% |
0.64 | 0.31 | 0.38 | 0.49 | 0.67 | 0.44 | 0.44 | 0.48 | 1.62 | 0.29 | 11.33 | 5.52 | |
Interest | 1.88 | 2.35 | 2.83 | 3.81 | 3.67 | 4.09 | 3.11 | 3.76 | 3.24 | 2.20 | 1.39 | 1.95 |
Depreciation | 0.17 | 0.26 | 0.24 | 0.14 | 0.06 | 0.05 | 0.03 | 0.12 | 0.12 | 0.27 | 0.64 | 0.95 |
Profit before tax | 0.42 | 0.70 | 0.73 | 0.92 | 1.53 | 0.89 | 0.42 | 0.28 | 1.10 | 1.16 | 2.26 | 1.17 |
Tax % | 16.67% | 38.57% | 50.68% | 27.17% | 32.68% | 22.47% | 26.19% | 32.14% | 27.27% | 21.55% | 32.74% | 26.50% |
0.35 | 0.43 | 0.35 | 0.66 | 1.03 | 0.69 | 0.31 | 0.19 | 0.80 | 0.91 | 1.53 | 0.86 | |
EPS in Rs | 8.37 | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 4% |
5 Years: | -2% |
3 Years: | -3% |
TTM: | -61% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 23% |
3 Years: | 2% |
TTM: | -44% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 7% |
3 Years: | -16% |
1 Year: | -40% |
Return on Equity | |
---|---|
10 Years: | 4% |
5 Years: | 3% |
3 Years: | 4% |
Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.67 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 |
Reserves | 5.55 | 5.98 | 6.33 | 6.99 | 8.03 | 13.78 | 18.14 | 18.33 | 19.13 | 19.93 | 21.46 | 22.42 |
18.58 | 27.50 | 27.83 | 22.08 | 21.75 | 31.22 | 29.93 | 27.07 | 21.11 | 18.94 | 16.43 | 20.86 | |
7.07 | 8.39 | 9.91 | 26.40 | 27.86 | 37.19 | 19.12 | 18.83 | 24.68 | 14.16 | 56.37 | 50.70 | |
Total Liabilities | 31.62 | 42.29 | 44.49 | 55.89 | 58.06 | 82.86 | 74.74 | 71.78 | 72.47 | 60.58 | 101.81 | 101.53 |
1.02 | 0.87 | 0.69 | 0.55 | 0.51 | 0.46 | 0.44 | 0.42 | 0.47 | 0.73 | 2.52 | 2.62 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 4.64 | 1.05 | 4.03 | 0.75 | 0.00 | 0.22 | 0.11 | 0.13 | 0.14 |
30.60 | 41.42 | 43.80 | 50.70 | 56.50 | 78.37 | 73.55 | 71.36 | 71.78 | 59.74 | 99.16 | 98.77 | |
Total Assets | 31.62 | 42.29 | 44.49 | 55.89 | 58.06 | 82.86 | 74.74 | 71.78 | 72.47 | 60.58 | 101.81 | 101.53 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | -9.03 | -6.18 | 4.05 | -7.41 | 8.33 | 12.40 | 5.26 | 6.18 | -5.71 | |
0.00 | 0.00 | 0.00 | 0.30 | -0.36 | -0.40 | 0.05 | 0.12 | 0.09 | -0.06 | -1.85 | -0.78 | |
0.00 | 0.00 | 0.00 | 7.97 | 6.51 | -3.73 | 6.94 | -6.42 | -9.62 | -4.45 | -5.80 | 2.19 | |
Net Cash Flow | 0.00 | 0.00 | 0.00 | -0.75 | -0.02 | -0.08 | -0.43 | 2.02 | 2.86 | 0.76 | -1.48 | -4.30 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 65.15 | 70.99 | 66.15 | 79.92 | 67.16 | 90.32 | 54.50 | 79.61 | 58.22 | 24.98 | 65.05 | 151.31 |
Inventory Days | 161.44 | 176.71 | 122.83 | 132.66 | 144.60 | 173.53 | 186.75 | 214.70 | 153.25 | 99.59 | 15.23 | 3.44 |
Days Payable | 53.01 | 43.18 | 32.81 | 80.69 | 68.58 | 117.37 | 53.13 | 78.51 | 11.98 | 10.62 | 23.21 | 44.58 |
Cash Conversion Cycle | 173.59 | 204.52 | 156.17 | 131.89 | 143.18 | 146.48 | 188.12 | 215.80 | 199.49 | 113.95 | 57.06 | 110.17 |
Working Capital Days | 148.78 | 166.47 | 133.63 | 124.96 | 138.50 | 139.43 | 212.16 | 257.87 | 164.88 | 120.81 | 60.64 | 194.07 |
ROCE % | 11.68% | 10.44% | 10.40% | 14.77% | 17.42% | 13.13% | 6.97% | 7.44% | 8.62% | 7.13% | 7.95% | 6.48% |
Documents
Announcements
-
Appointment Of Secretarial Auditor.
29 May - Appointment of Amit Dharmani & Associates as Secretarial Auditor for FY 2024-25.
-
Result For The Financial Year March 31 2025.
29 May - Approved audited FY25 financial results with unmodified opinion; appointed secretarial auditor; trading window closed.
-
Board Meeting Outcome for Outcome Of Board Meeting
29 May - Approved audited financial results FY 2024-25 with unmodified audit opinion; trading window reopens after 48 hours.
-
Board Meeting Intimation for Approval Of Audited Financial Statement As On March 31, 2025.
24 May - Board meeting on 29 May 2025 to consider audited financials for half and full year ended 31 March 2025.
-
General-Updates
21 Apr - Exempt from corporate governance compliance for Q4 FY25 as listed on SME Exchange.
Business Overview:[1][2]
Company manufactures formulations and does trading of API in domestic and international markets through its own distribution network and Sales force, under the brand name CBC.
It manufactures formulations by outsourcing to third party on job work basis
a) Major focus on Injection viz. ITV (Intravenous) & IM (Intramuscular), tablets and capsules supply to Hospital and Health care Centre for critical diseases
b) Getting approved formulations manufactured through Contract Manufacturers, Source & Supply of Generic and branded Pharma formulations and medicines to healthcare institution, Government, NGO’s, Hospitals & Distributors
c) Source, deal in Import, indenting and Supply in Specialty Chemicals, Intermediates & Active Pharmaceuticals Ingredients (API)